Krystal Biotech: Vanguard reports 4.43% stake
The reported securities include Vanguard fund holdings and client-account securities over which the named affiliates or business divisions exercise voting or dispositive power.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Krystal Biotech, Inc. (KRYS) is the issuer of the shares for which Vanguard Portfolio Management reported beneficial ownership of 1,312,431 shares, or 4.43%, as of September 30, 2026. Vanguard reported sole dispositive power over 1,312,431 shares and sole voting power over 25,577 shares; shared voting and dispositive power were both zero. The disclosure attributes the reported holdings to Vanguard Portfolio Management LLC and specified affiliates or business divisions. It states that no other person's interest in the reported securities exceeds 5%.
Key Figures
Key Terms
beneficially owned regulatory
Sole Dispositive Power regulatory
Sole Voting Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.